https://www.321223.comnone https://www.321223.com/xwdt/xydt/ https://www.321223.com/xwdt/xjz/ https://www.321223.com/xwdt/html/990.html https://www.321223.com/xwdt/html/979.html https://www.321223.com/xwdt/html/967.html https://www.321223.com/xwdt/html/943.html https://www.321223.com/xwdt/html/927.html https://www.321223.com/xwdt/html/907.html https://www.321223.com/xwdt/html/900.html https://www.321223.com/xwdt/html/897.html https://www.321223.com/xwdt/html/729.html https://www.321223.com/xwdt/html/656.html https://www.321223.com/xwdt/html/592.html https://www.321223.com/xwdt/html/575.html https://www.321223.com/xwdt/html/557.html https://www.321223.com/xwdt/html/488.html https://www.321223.com/xwdt/html/465.html https://www.321223.com/xwdt/html/419.html https://www.321223.com/xwdt/html/348.html https://www.321223.com/xwdt/html/314.html https://www.321223.com/xwdt/html/270.html https://www.321223.com/xwdt/html/233.html https://www.321223.com/xwdt/html/1310.html https://www.321223.com/xwdt/html/1304.html https://www.321223.com/xwdt/html/1303.html https://www.321223.com/xwdt/html/1302.html https://www.321223.com/xwdt/html/1301.html https://www.321223.com/xwdt/html/1300.html https://www.321223.com/xwdt/html/1297.html https://www.321223.com/xwdt/html/1296.html https://www.321223.com/xwdt/html/1295.html https://www.321223.com/xwdt/html/1294.html https://www.321223.com/xwdt/html/1286.html https://www.321223.com/xwdt/html/1275.html https://www.321223.com/xwdt/html/1274.html https://www.321223.com/xwdt/html/1273.html https://www.321223.com/xwdt/html/1272.html https://www.321223.com/xwdt/html/1271.html https://www.321223.com/xwdt/html/1270.html https://www.321223.com/xwdt/html/1259.html https://www.321223.com/xwdt/html/1258.html https://www.321223.com/xwdt/html/1257.html https://www.321223.com/xwdt/html/1256.html https://www.321223.com/xwdt/html/1255.html https://www.321223.com/xwdt/html/1254.html https://www.321223.com/xwdt/html/1253.html https://www.321223.com/xwdt/html/1251.html https://www.321223.com/xwdt/html/1250.html https://www.321223.com/xwdt/html/1249.html https://www.321223.com/xwdt/html/1248.html https://www.321223.com/xwdt/html/1247.html https://www.321223.com/xwdt/html/1246.html https://www.321223.com/xwdt/html/1245.html https://www.321223.com/xwdt/html/1241.html https://www.321223.com/xwdt/html/1240.html https://www.321223.com/xwdt/html/1235.html https://www.321223.com/xwdt/html/1234.html https://www.321223.com/xwdt/html/1226.html https://www.321223.com/xwdt/html/1225.html https://www.321223.com/xwdt/html/1224.html https://www.321223.com/xwdt/html/1200.html https://www.321223.com/xwdt/html/1199.html https://www.321223.com/xwdt/gsxw/ https://www.321223.com/media/zyupr30a/hkex-eps_20260930_12354321_0.pdf https://www.321223.com/media/znwhl4oq/final-2025-esmo-ct041-poster.pdf https://www.321223.com/media/xvghsvht/2022-interim-report.pdf https://www.321223.com/media/xmlelc50/poster_abstract-2557.pdf https://www.321223.com/media/wsnbvqta/通用型car-t产品ct0596及ct1190b的积极临床数据.pdf https://www.321223.com/media/wsnbvqta/ͨ����car-t��Ʒct0596��ct1190b�Ļ����ٴ�����.pdf https://www.321223.com/media/wncfkrfb/公示件-泽沃基奥仑赛注射液使用培训和认证的医疗机构名单汇总-0720.pdf https://www.321223.com/media/wivjdipc/2023-hy.pdf https://www.321223.com/media/wccjzwma/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b.pdf https://www.321223.com/media/vujmc2eu/green-application-form.pdf https://www.321223.com/media/vtudbnl4/final-2025-asco-oral-presentation.pdf https://www.321223.com/media/vtoc44bj/en_hkex-eps_20240909_11360644_0.pdf https://www.321223.com/media/vbnbibn2/general_terms_and_conditions_of_purchase_carsgen_us_final_20231110.pdf https://www.321223.com/media/ub5lsa0p/car-tcr-summit-2022-final.pdf https://www.321223.com/media/u1wdz4jn/hkex-eps_20241210_11472656_0.pdf https://www.321223.com/media/tz2paqen/global-offering-2-cn.pdf https://www.321223.com/media/txzffkap/hkex-eps_20221209_10538157_0fan.pdf https://www.321223.com/media/tu3jixci/hkex-eps_20230419_10692749_0_en.pdf https://www.321223.com/media/t5zguoik/hkex-eps_20260930_12354322_0.pdf https://www.321223.com/media/t5knxqvb/1751.pdf https://www.321223.com/media/syrk40jm/final-carsgen-therapeutics-corporate-deck_oct-28.pdf https://www.321223.com/media/suzbnpln/eha-2025-ct071-pf1164_juan-du.pdf https://www.321223.com/media/stwjmue4/final-�Ƽ�ҩҵ��˾����-oct-13.pdf https://www.321223.com/media/stwjmue4/final-Z6尊龙凯时药业公司介绍-oct-13.pdf https://www.321223.com/media/rzmju0v4/ct0596-eha2026-poster-final-1.pdf https://www.321223.com/media/rqfnslii/2024041800870_c.pdf https://www.321223.com/media/pudgixhi/aacr-cldn18-2-poster.pdf https://www.321223.com/media/pp2bzlw0/�Ƽ�ҩҵ2025Ͷ���߿�����.pdf https://www.321223.com/media/pp2bzlw0/Z6尊龙凯时药业2025投资者盛开日.pdf https://www.321223.com/media/pmglacuc/2023-hy-e.pdf https://www.321223.com/media/pjrcksuy/global-offering.pdf https://www.321223.com/media/oy2arfcg/poster-1056p.pdf https://www.321223.com/media/otzepuxu/contractual-arrangements-which-are-material-contracts.pdf https://www.321223.com/media/o3nbxckn/2022-ash.pdf https://www.321223.com/media/o2hhwg5j/procedures-for-shareholders-to-propose-directors-en.pdf https://www.321223.com/media/nfkjdysh/e_ham25051660ann-20250904-20250904_1323.pdf https://www.321223.com/media/n2ih2b4l/carsgen-therapeutics-2025-investor-day.pdf https://www.321223.com/media/mi3ppjp2/final-�Ƽ�ҩҵ��˾����-oct-28.pdf https://www.321223.com/media/mi3ppjp2/final-Z6尊龙凯时药业公司介绍-oct-28.pdf https://www.321223.com/media/mckjltow/2025-interim-report.pdf https://www.321223.com/media/mbijtrcb/final-�Ƽ�ҩҵ��˾����-sept-1.pdf https://www.321223.com/media/mbijtrcb/final-Z6尊龙凯时药业公司介绍-sept-1.pdf https://www.321223.com/media/malcgk31/green-application-form-cn.pdf https://www.321223.com/media/lzxm1ezb/4845_ash-poster.pdf https://www.321223.com/media/lwmjqyw3/2821.pdf https://www.321223.com/media/llznor0x/2023-asco-gi-poster_ab011-mono-combo-_0106final.pdf https://www.321223.com/media/lgei54pn/global-offering-2.pdf https://www.321223.com/media/kv3nfwei/2021-annual-report-en.pdf https://www.321223.com/media/kuxd30iu/final-carsgen-therapeutics-corporate-deck_sept-1.pdf https://www.321223.com/media/kolhjqpf/2022-interim-report-cn.pdf https://www.321223.com/media/jyyh33c4/2021-esmo-ct041-oral-presentation.pdf https://www.321223.com/media/jyvpmslq/hkex-eps_20260915_12332734_0.pdf https://www.321223.com/media/iznib0sv/c_ham25051660ann-20250904-20250904_1325.pdf https://www.321223.com/media/i4bdwekv/carsgen_arrangements-of-electronic-dissemination-of-corporate-communications_en.pdf https://www.321223.com/media/hn1pbu44/2022_asco_annual_meeting_poster_14may2022.pdf https://www.321223.com/media/hiuks2qn/ct041-cg4006-asco-2024_v3-0_20240603-1.pdf https://www.321223.com/media/hgpk5qic/hkex-eps_20241210_11472655_0.pdf https://www.321223.com/media/ghcj2aj4/cn_hkex-eps_20240909_11360645_0.pdf https://www.321223.com/media/gdon4wmr/ct0596-ash-poster-20251110-for-submision.pdf https://www.321223.com/media/g4aoe02d/公示文件-舒瑞基奥仑赛注射液使用培训和认证的医疗机构名单-0720.pdf https://www.321223.com/media/fdyfi4ug/carsgen_arrangements-of-electronic-dissemination-of-corporate-communications_cn.pdf https://www.321223.com/media/f5pblhde/ct053-ash-poster_-4762.pdf https://www.321223.com/media/f1jny5l1/sitc-2023-poster.pdf https://www.321223.com/media/eb0lckhd/2021-esmo-ct041-口头汇报.pdf https://www.321223.com/media/eatjktro/hkex-eps_20260410_12102280_0.pdf https://www.321223.com/media/dxnj3spj/ct0590-ash-poster_-4843.pdf https://www.321223.com/media/djkf4urr/hkex-eps_20221209_10538156_0en.pdf https://www.321223.com/media/caaamxan/hkex-eps_20260522_12169562_0.pdf https://www.321223.com/media/brtijrlk/2021-annual-report.pdf https://www.321223.com/media/brqhxcy4/2024041800869.pdf https://www.321223.com/media/agmjug4b/final-eha2024-ppt-v2_clean_06.pdf https://www.321223.com/media/5yod15ea/abstract-4095_ct0180_poster.pdf https://www.321223.com/media/5owm5t4b/global-offering-cn.pdf https://www.321223.com/media/5drbms3p/2024-annual-report-c.pdf https://www.321223.com/media/4tejef2g/2025-interim-report-c.pdf https://www.321223.com/media/4hyptsvx/ct1190b-ps2064_ye-1.pdf https://www.321223.com/media/4cbfepok/hkex-eps_20260915_12332733_0.pdf https://www.321223.com/media/3vsj00ph/2024-annual-report.pdf https://www.321223.com/media/3bzk0o35/hkex-eps_20260522_12169561_0.pdf https://www.321223.com/media/3byc3vpp/hkex-eps_20230419_10692750_0_hk.pdf https://www.321223.com/media/2w4bh31e/procedures-for-shareholders-to-propose-directors-cn.pdf https://www.321223.com/media/2rwlk1zn/final-carsgen-therapeutics-corporate-deck_oct-13.pdf https://www.321223.com/media/2kygbdc3/final-p941_du.pdf https://www.321223.com/media/1w1dumr5/final-ims_poster_pa-029_id-number-3173032-v2-1.pdf https://www.321223.com/media/1s3dnn3g/blue-asco-poster-gpb-05-19-2023-final.pdf https://www.321223.com/media/1rjd2yul/hkex-eps_20260410_12102281_0.pdf https://www.321223.com/media/1gwa3sdq/ct041-st-02-phase-1b-cohort-a-2024-asco-gi-poster_final.pdf https://www.321223.com/media/0yylooxm/ct071-ash-poster_-3451.pdf https://www.321223.com/media/0klf3v3t/ct041-st-01-abs4017-poster_final.pdf https://www.321223.com/lxwm/ https://www.321223.com/jrwm/ https://www.321223.com/jjfa/ https://www.321223.com/html/web/xinwenzhongxin/shipinzhuanqu/index.html https://www.321223.com/html/web/xinwenzhongxin/fangdaxinwen/index.html https://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/index.html https://www.321223.com/html/web/touziyuhezuo/shangshigongsi/index.html https://www.321223.com/html/web/shehuizeren/zhichiguofang/index.html https://www.321223.com/html/web/shehuizeren/yifanashui/index.html https://www.321223.com/html/web/shehuizeren/shehuigongyi/index.html https://www.321223.com/html/web/shehuizeren/jienenghuanbao/index.html https://www.321223.com/html/web/shehuizeren/baozhangjiuye/index.html https://www.321223.com/html/web/rencaifazhan/zhaopingonggao/index.html https://www.321223.com/html/web/guanyuwomen/zuzhijiagou/index.html https://www.321223.com/html/web/guanyuwomen/fazhanlicheng/index.html https://www.321223.com/html/web/guanyuwomen/fangdarongyu/index.html https://www.321223.com/html/web/guanyuwomen/fangdajianjie/index.html https://www.321223.com/html/web/dangjianwenhua/xingfufangda/index.html https://www.321223.com/html/web/dangjianwenhua/qiyelinian/index.html https://www.321223.com/html/web/dangjianwenhua/dangqunhuodong/index.html https://www.321223.com/html/web/chengyuandanwei/yiyao/index.html https://www.321223.com/html/web/chengyuandanwei/tansu/index.html https://www.321223.com/html/web/chengyuandanwei/shangye/index.html https://www.321223.com/html/web/chengyuandanwei/hangkong/index.html https://www.321223.com/html/web/chengyuandanwei/gangtie/index.html https://www.321223.com/hk/privacy-policy/ https://www.321223.com/hk/pipeline/ https://www.321223.com/hk/our-approach/technologies/ https://www.321223.com/hk/our-approach/publications/?page=1 https://www.321223.com/hk/our-approach/publications/ https://www.321223.com/hk/our-approach/manufacturing/ https://www.321223.com/hk/our-approach/ https://www.321223.com/hk/news/�Ƽ�ҩҵct041����asco-�״ι�������ע���ٴ���������/ https://www.321223.com/hk/news/?page=4 https://www.321223.com/hk/news/?page=3 https://www.321223.com/hk/news/?page=2 https://www.321223.com/hk/news/?page=1 https://www.321223.com/hk/news/20191209/ https://www.321223.com/hk/news/20190301/ https://www.321223.com/hk/news/20190129/ https://www.321223.com/hk/news/20190128/ https://www.321223.com/hk/news/20170810/ https://www.321223.com/hk/news/ https://www.321223.com/hk/investors/listing-documents/ https://www.321223.com/hk/investors/ir-contact/ https://www.321223.com/hk/investors/financial-reports/ https://www.321223.com/hk/investors/corporate-governance/ https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=5 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=4 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=3 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=2 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=1 https://www.321223.com/hk/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/ https://www.321223.com/hk/investors/corporate-deck-presentations/?page=5 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=4 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=3 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=2 https://www.321223.com/hk/investors/corporate-deck-presentations/?page=1 https://www.321223.com/hk/investors/corporate-deck-presentations/ https://www.321223.com/hk/investors/announcements-circulars/ https://www.321223.com/hk/investors/ https://www.321223.com/hk/disclaimer/ https://www.321223.com/hk/contact-us/ https://www.321223.com/hk/careers/join-us/ https://www.321223.com/hk/careers/ https://www.321223.com/hk/about-us/vision-mission-values/ https://www.321223.com/hk/about-us/partnering/ https://www.321223.com/hk/about-us/company-overview/ https://www.321223.com/hk/about-us/ https://www.321223.com/hk/ https://www.321223.com/gydk/ryzz/ https://www.321223.com/gydk/qysl/ https://www.321223.com/gydk/gywm/ https://www.321223.com/en/privacy-policy/ https://www.321223.com/en/pipeline/new-pipeline/mab/kj-c2630/ https://www.321223.com/en/pipeline/new-pipeline/mab/kj-c2527/ https://www.321223.com/en/pipeline/new-pipeline/mab/kj-c2526/ https://www.321223.com/en/pipeline/new-pipeline/mab/ct1390b/ https://www.321223.com/en/pipeline/new-pipeline/mab/ct1190b-kj-c2219/ https://www.321223.com/en/pipeline/new-pipeline/mab/ct0596/ https://www.321223.com/en/pipeline/new-pipeline/mab/ https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2635/ https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2634/ https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2633/ https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2632/ https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/kj-c2529/ https://www.321223.com/en/pipeline/new-pipeline/in-vivo-car-t/ https://www.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/zevor-cel-ct053-3/ https://www.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/ct041/ https://www.321223.com/en/pipeline/new-pipeline/car-t-cell-therapies/ https://www.321223.com/en/pipeline/new-pipeline/ https://www.321223.com/en/pipeline/expanded-access/ https://www.321223.com/en/pipeline/ https://www.321223.com/en/our-approach/technologies/ https://www.321223.com/en/our-approach/publications/zevorcabtagene-autoleucel-first-approval/ https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-κb-icam1-signaling/ https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-��b-icam1-signaling/ https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=5 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=4 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=2 https://www.321223.com/en/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=1 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=4 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=2 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=1 https://www.321223.com/en/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/ https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=5 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=4 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=2 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=1 https://www.321223.com/en/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/ https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=5 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=4 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=2 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=1 https://www.321223.com/en/our-approach/publications/combined-local-therapy-and-car-gpc3/ https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=5 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=4 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=2 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=1 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/ https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=4 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=2 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=1 https://www.321223.com/en/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/ https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3ε-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3��-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=5 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=4 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=2 https://www.321223.com/en/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=1 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=4 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=2 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=1 https://www.321223.com/en/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/ https://www.321223.com/en/our-approach/publications/?page=5 https://www.321223.com/en/our-approach/publications/?page=4 https://www.321223.com/en/our-approach/publications/?page=3 https://www.321223.com/en/our-approach/publications/?page=2 https://www.321223.com/en/our-approach/publications/?page=1 https://www.321223.com/en/our-approach/publications/20261001/ https://www.321223.com/en/our-approach/publications/20260918/?page=5 https://www.321223.com/en/our-approach/publications/20260918/?page=4 https://www.321223.com/en/our-approach/publications/20260918/?page=2 https://www.321223.com/en/our-approach/publications/20260918/?page=1 https://www.321223.com/en/our-approach/publications/20260918/ https://www.321223.com/en/our-approach/publications/20251029/?page=5 https://www.321223.com/en/our-approach/publications/20251029/?page=4 https://www.321223.com/en/our-approach/publications/20251029/?page=2 https://www.321223.com/en/our-approach/publications/20251029/?page=1 https://www.321223.com/en/our-approach/publications/20251029/ https://www.321223.com/en/our-approach/publications/20251008/?page=4 https://www.321223.com/en/our-approach/publications/20251008/?page=2 https://www.321223.com/en/our-approach/publications/20251008/?page=1 https://www.321223.com/en/our-approach/publications/20251008/ https://www.321223.com/en/our-approach/publications/20250930/?page=4 https://www.321223.com/en/our-approach/publications/20250930/?page=2 https://www.321223.com/en/our-approach/publications/20250930/?page=1 https://www.321223.com/en/our-approach/publications/20250930/ https://www.321223.com/en/our-approach/publications/20250531/?page=5 https://www.321223.com/en/our-approach/publications/20250531/?page=4 https://www.321223.com/en/our-approach/publications/20250531/?page=2 https://www.321223.com/en/our-approach/publications/20250531/?page=1 https://www.321223.com/en/our-approach/publications/20250531/ https://www.321223.com/en/our-approach/publications/20240524/?page=5 https://www.321223.com/en/our-approach/publications/20240524/?page=4 https://www.321223.com/en/our-approach/publications/20240524/?page=2 https://www.321223.com/en/our-approach/publications/20240524/?page=1 https://www.321223.com/en/our-approach/publications/20240524/ https://www.321223.com/en/our-approach/publications/20240311/?page=5 https://www.321223.com/en/our-approach/publications/20240311/?page=4 https://www.321223.com/en/our-approach/publications/20240311/?page=2 https://www.321223.com/en/our-approach/publications/20240311/?page=1 https://www.321223.com/en/our-approach/publications/20240311/ https://www.321223.com/en/our-approach/publications/20240205/?page=5 https://www.321223.com/en/our-approach/publications/20240205/?page=4 https://www.321223.com/en/our-approach/publications/20240205/?page=2 https://www.321223.com/en/our-approach/publications/20240205/?page=1 https://www.321223.com/en/our-approach/publications/20240205/ https://www.321223.com/en/our-approach/publications/20230920/?page=4 https://www.321223.com/en/our-approach/publications/20230920/?page=2 https://www.321223.com/en/our-approach/publications/20230920/?page=1 https://www.321223.com/en/our-approach/publications/20230920/ https://www.321223.com/en/our-approach/publications/20230909/?page=5 https://www.321223.com/en/our-approach/publications/20230909/?page=4 https://www.321223.com/en/our-approach/publications/20230909/?page=2 https://www.321223.com/en/our-approach/publications/20230909/?page=1 https://www.321223.com/en/our-approach/publications/20230909/ https://www.321223.com/en/our-approach/publications/20230830/?page=5 https://www.321223.com/en/our-approach/publications/20230830/?page=4 https://www.321223.com/en/our-approach/publications/20230830/?page=2 https://www.321223.com/en/our-approach/publications/20230830/?page=1 https://www.321223.com/en/our-approach/publications/20230830/ https://www.321223.com/en/our-approach/publications/20221215/?page=4 https://www.321223.com/en/our-approach/publications/20221215/?page=2 https://www.321223.com/en/our-approach/publications/20221215/?page=1 https://www.321223.com/en/our-approach/publications/20221215/ https://www.321223.com/en/our-approach/publications/20220817/?page=4 https://www.321223.com/en/our-approach/publications/20220817/?page=2 https://www.321223.com/en/our-approach/publications/20220817/?page=1 https://www.321223.com/en/our-approach/publications/20220817/ https://www.321223.com/en/our-approach/publications/20201001/?page=4 https://www.321223.com/en/our-approach/publications/20201001/?page=2 https://www.321223.com/en/our-approach/publications/20201001/?page=1 https://www.321223.com/en/our-approach/publications/20201001/ https://www.321223.com/en/our-approach/publications/20200925/ https://www.321223.com/en/our-approach/publications/20200801/?page=4 https://www.321223.com/en/our-approach/publications/20200801/?page=2 https://www.321223.com/en/our-approach/publications/20200801/?page=1 https://www.321223.com/en/our-approach/publications/20200801/ https://www.321223.com/en/our-approach/publications/20200121/?page=4 https://www.321223.com/en/our-approach/publications/20200121/?page=2 https://www.321223.com/en/our-approach/publications/20200121/?page=1 https://www.321223.com/en/our-approach/publications/20200121/ https://www.321223.com/en/our-approach/publications/20191219/?page=4 https://www.321223.com/en/our-approach/publications/20191219/?page=2 https://www.321223.com/en/our-approach/publications/20191219/?page=1 https://www.321223.com/en/our-approach/publications/20191219/ https://www.321223.com/en/our-approach/publications/20190920/?page=5 https://www.321223.com/en/our-approach/publications/20190920/?page=4 https://www.321223.com/en/our-approach/publications/20190920/?page=2 https://www.321223.com/en/our-approach/publications/20190920/?page=1 https://www.321223.com/en/our-approach/publications/20190920/ https://www.321223.com/en/our-approach/publications/20190701/?page=4 https://www.321223.com/en/our-approach/publications/20190701/?page=2 https://www.321223.com/en/our-approach/publications/20190701/?page=1 https://www.321223.com/en/our-approach/publications/20190701/ https://www.321223.com/en/our-approach/publications/20190429/ https://www.321223.com/en/our-approach/publications/20190417/?page=4 https://www.321223.com/en/our-approach/publications/20190417/?page=2 https://www.321223.com/en/our-approach/publications/20190417/?page=1 https://www.321223.com/en/our-approach/publications/20190417/ https://www.321223.com/en/our-approach/publications/20181101/?page=5 https://www.321223.com/en/our-approach/publications/20181101/?page=4 https://www.321223.com/en/our-approach/publications/20181101/?page=2 https://www.321223.com/en/our-approach/publications/20181101/?page=1 https://www.321223.com/en/our-approach/publications/20181101/ https://www.321223.com/en/our-approach/publications/20181001/?page=5 https://www.321223.com/en/our-approach/publications/20181001/?page=4 https://www.321223.com/en/our-approach/publications/20181001/?page=2 https://www.321223.com/en/our-approach/publications/20181001/?page=1 https://www.321223.com/en/our-approach/publications/20181001/ https://www.321223.com/en/our-approach/publications/20180906/ https://www.321223.com/en/our-approach/publications/20180804/?page=4 https://www.321223.com/en/our-approach/publications/20180804/?page=2 https://www.321223.com/en/our-approach/publications/20180804/?page=1 https://www.321223.com/en/our-approach/publications/20180804/ https://www.321223.com/en/our-approach/publications/20171218/?page=4 https://www.321223.com/en/our-approach/publications/20171218/?page=2 https://www.321223.com/en/our-approach/publications/20171218/?page=1 https://www.321223.com/en/our-approach/publications/20171218/ https://www.321223.com/en/our-approach/publications/20170919/?page=4 https://www.321223.com/en/our-approach/publications/20170919/?page=2 https://www.321223.com/en/our-approach/publications/20170919/?page=1 https://www.321223.com/en/our-approach/publications/20170919/ https://www.321223.com/en/our-approach/publications/20170703/?page=5 https://www.321223.com/en/our-approach/publications/20170703/?page=4 https://www.321223.com/en/our-approach/publications/20170703/?page=2 https://www.321223.com/en/our-approach/publications/20170703/?page=1 https://www.321223.com/en/our-approach/publications/20170703/ https://www.321223.com/en/our-approach/publications/20170516/?page=4 https://www.321223.com/en/our-approach/publications/20170516/?page=2 https://www.321223.com/en/our-approach/publications/20170516/?page=1 https://www.321223.com/en/our-approach/publications/20170516/ https://www.321223.com/en/our-approach/publications/20161229/?page=5 https://www.321223.com/en/our-approach/publications/20161229/?page=4 https://www.321223.com/en/our-approach/publications/20161229/?page=2 https://www.321223.com/en/our-approach/publications/20161229/?page=1 https://www.321223.com/en/our-approach/publications/20161229/ https://www.321223.com/en/our-approach/publications/ https://www.321223.com/en/our-approach/manufacturing/ https://www.321223.com/en/our-approach/ https://www.321223.com/en/news/?page=2 https://www.321223.com/en/news/?page=13 https://www.321223.com/en/news/?page=1 https://www.321223.com/en/news/20261026/ https://www.321223.com/en/news/20261013/ https://www.321223.com/en/news/20260929/ https://www.321223.com/en/news/20260819/ https://www.321223.com/en/news/20260807/ https://www.321223.com/en/news/20260804/ https://www.321223.com/en/news/20260715/ https://www.321223.com/en/news/20260622/ https://www.321223.com/en/news/20260615/ https://www.321223.com/en/news/20260601/ https://www.321223.com/en/news/20260521/ https://www.321223.com/en/news/20260512/ https://www.321223.com/en/news/20260428/ https://www.321223.com/en/news/20260309/ https://www.321223.com/en/news/20260306/ https://www.321223.com/en/news/20260213/ https://www.321223.com/en/news/20260112/ https://www.321223.com/en/news/20251229/ https://www.321223.com/en/news/2023-08-21/ https://www.321223.com/en/news/20190129/ https://www.321223.com/en/news/ https://www.321223.com/en/investors/listing-documents/ https://www.321223.com/en/investors/ir-contact/ https://www.321223.com/en/investors/financial-reports/ https://www.321223.com/en/investors/corporate-governance/ https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/webcasts/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/positive-clinical-data-for-allogeneic-car-t-products-ct0596-and-ct1190b/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20261026/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20260601/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251207/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20251119/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2025-asco-claudin18-2-specific-car-t-cells-satri-cel-versus-treatment-of-physician-s-choice-tpc-for-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-g-gejc-primary-results-from-a-randomized-open-label-phase-ii-trial-c/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20240119/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/20231212/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-gi-a-multicenter-phase-1-study-of-ab011-a-recombinant-humanized-anti-cldn18-2-monoclonal-antibody-ab011-as-monotherapy-and-combined-with-capecitabine-and-oxaliplatin-capox-in-patients-with-advanced-solid-tumors/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-2/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-asco-1/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2023-aacr/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=6 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/ https://www.321223.com/en/investors/corporate-deck-presentations/presentations/ https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/corporate-deck/ https://www.321223.com/en/investors/corporate-deck-presentations/?page=5 https://www.321223.com/en/investors/corporate-deck-presentations/?page=4 https://www.321223.com/en/investors/corporate-deck-presentations/?page=3 https://www.321223.com/en/investors/corporate-deck-presentations/?page=2 https://www.321223.com/en/investors/corporate-deck-presentations/?page=1 https://www.321223.com/en/investors/corporate-deck-presentations/ https://www.321223.com/en/investors/announcements-circulars/ https://www.321223.com/en/investors/ https://www.321223.com/en/disclaimer/ https://www.321223.com/en/contact-us/ https://www.321223.com/en/careers/join-us/ https://www.321223.com/en/careers/ https://www.321223.com/en/about-us/vision-mission-values/ https://www.321223.com/en/about-us/partnering/ https://www.321223.com/en/about-us/leadership/ https://www.321223.com/en/about-us/company-overview/ https://www.321223.com/en/about-us/ https://www.321223.com/en/" https://www.321223.com/en/ https://www.321223.com/cpzs/html/179.html https://www.321223.com/cpzs/html/178.html https://www.321223.com/cpzs/html/177.html https://www.321223.com/cpzs/html/176.html https://www.321223.com/cpzs/html/174.html https://www.321223.com/cpzs/html/173.html https://www.321223.com/cpzs/html/172.html https://www.321223.com/cpzs/html/171.html https://www.321223.com/cpzs/html/170.html https://www.321223.com/cpzs/html/169.html https://www.321223.com/cpzs/html/168.html https://www.321223.com/cpzs/html/167.html https://www.321223.com/cpzs/html/166.html https://www.321223.com/cpzs/ https://www.321223.com/cn/privacy-policy/ https://www.321223.com/cn/pipeline/zevor-cel/ https://www.321223.com/cn/pipeline/satri-cel/ https://www.321223.com/cn/pipeline/new-pipeline/mab/kj-c2630/ https://www.321223.com/cn/pipeline/new-pipeline/mab/kj-c2527/ https://www.321223.com/cn/pipeline/new-pipeline/mab/kj-c2526/ https://www.321223.com/cn/pipeline/new-pipeline/mab/ct1390b/ https://www.321223.com/cn/pipeline/new-pipeline/mab/ct1190b-kj-c2219/ https://www.321223.com/cn/pipeline/new-pipeline/mab/ct0596/ https://www.321223.com/cn/pipeline/new-pipeline/mab/ https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2635/ https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2634/ https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2633/ https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2632/ https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/kj-c2529/ https://www.321223.com/cn/pipeline/new-pipeline/in-vivo-car-t/ https://www.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/zevor-cel-ct053-3/ https://www.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/ct041/ https://www.321223.com/cn/pipeline/new-pipeline/car-t-cell-therapies/ https://www.321223.com/cn/pipeline/new-pipeline/ https://www.321223.com/cn/pipeline/expanded-access/ https://www.321223.com/cn/pipeline/ https://www.321223.com/cn/our-approach/technologies/ https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=5 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=4 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=2 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/?page=1 https://www.321223.com/cn/our-approach/publications/zevorcabtagene-autoleucel-first-approval/ https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-κb-icam1-signaling/ https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-��b-icam1-signaling/ https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=5 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=4 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=2 https://www.321223.com/cn/our-approach/publications/radiation-enhances-the-efficacy-of-egfr-targeted-car-t-cells-against-triple-negative-breast-cancer-by-activating-nf-%CE%BAb-icam1-signaling/?page=1 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=4 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=2 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/?page=1 https://www.321223.com/cn/our-approach/publications/fap-targeted-car-t-suppresses-mdscs-recruitment-to-improve-the-antitumor-efficacy-of-claudin18-2-targeted-car-t-against-pancreatic-cancer/ https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=5 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=4 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=2 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/?page=1 https://www.321223.com/cn/our-approach/publications/expressing-il-15-il-18-and-cxcr2-improve-infiltration-and-survival-of-egfrviii-targeting-car-t-cells-in-breast-cancer/ https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=5 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=4 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=2 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/?page=1 https://www.321223.com/cn/our-approach/publications/combined-local-therapy-and-car-gpc3/ https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=5 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=4 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=2 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/?page=1 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-interim-results/ https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=5 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=4 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=2 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/?page=1 https://www.321223.com/cn/our-approach/publications/claudin18-2-specific-car-t-cells-in-gastrointestinal-cancers-phase-1-trial-final-results/ https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3ε-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3��-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/ https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=4 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=2 https://www.321223.com/cn/our-approach/publications/chimeric-anti-gpc3-sfv-cd3%CE%B5-receptor-modified-t-cells-with-il7-co-expression-for-the-treatment-of-solid-tumors/?page=1 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=5 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=4 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=2 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/?page=1 https://www.321223.com/cn/our-approach/publications/a-novel-bcma-car-t-cell-therapy-with-optimized-human-scfv-for-treatment-of-relapsed-refractory-multiple-myeloma-results-from-phase-i-clinical-trials/ https://www.321223.com/cn/our-approach/publications/?page=5 https://www.321223.com/cn/our-approach/publications/?page=4 https://www.321223.com/cn/our-approach/publications/?page=3 https://www.321223.com/cn/our-approach/publications/?page=2 https://www.321223.com/cn/our-approach/publications/?page=1 https://www.321223.com/cn/our-approach/publications/20261001/ https://www.321223.com/cn/our-approach/publications/20260918/?page=4 https://www.321223.com/cn/our-approach/publications/20260918/?page=2 https://www.321223.com/cn/our-approach/publications/20260918/?page=1 https://www.321223.com/cn/our-approach/publications/20260918/ https://www.321223.com/cn/our-approach/publications/20251029/?page=4 https://www.321223.com/cn/our-approach/publications/20251029/?page=2 https://www.321223.com/cn/our-approach/publications/20251029/?page=1 https://www.321223.com/cn/our-approach/publications/20251029/ https://www.321223.com/cn/our-approach/publications/20251008/?page=4 https://www.321223.com/cn/our-approach/publications/20251008/?page=2 https://www.321223.com/cn/our-approach/publications/20251008/?page=1 https://www.321223.com/cn/our-approach/publications/20251008/ https://www.321223.com/cn/our-approach/publications/20250930/?page=5 https://www.321223.com/cn/our-approach/publications/20250930/?page=4 https://www.321223.com/cn/our-approach/publications/20250930/?page=2 https://www.321223.com/cn/our-approach/publications/20250930/?page=1 https://www.321223.com/cn/our-approach/publications/20250930/ https://www.321223.com/cn/our-approach/publications/20250531/?page=5 https://www.321223.com/cn/our-approach/publications/20250531/?page=4 https://www.321223.com/cn/our-approach/publications/20250531/?page=2 https://www.321223.com/cn/our-approach/publications/20250531/?page=1 https://www.321223.com/cn/our-approach/publications/20250531/ https://www.321223.com/cn/our-approach/publications/20240524/?page=5 https://www.321223.com/cn/our-approach/publications/20240524/?page=4 https://www.321223.com/cn/our-approach/publications/20240524/?page=2 https://www.321223.com/cn/our-approach/publications/20240524/?page=1 https://www.321223.com/cn/our-approach/publications/20240524/ https://www.321223.com/cn/our-approach/publications/20240311/?page=4 https://www.321223.com/cn/our-approach/publications/20240311/?page=2 https://www.321223.com/cn/our-approach/publications/20240311/?page=1 https://www.321223.com/cn/our-approach/publications/20240311/ https://www.321223.com/cn/our-approach/publications/20240205/?page=5 https://www.321223.com/cn/our-approach/publications/20240205/?page=4 https://www.321223.com/cn/our-approach/publications/20240205/?page=2 https://www.321223.com/cn/our-approach/publications/20240205/?page=1 https://www.321223.com/cn/our-approach/publications/20240205/ https://www.321223.com/cn/our-approach/publications/20230920/?page=5 https://www.321223.com/cn/our-approach/publications/20230920/?page=4 https://www.321223.com/cn/our-approach/publications/20230920/?page=2 https://www.321223.com/cn/our-approach/publications/20230920/?page=1 https://www.321223.com/cn/our-approach/publications/20230920/ https://www.321223.com/cn/our-approach/publications/20230909/?page=5 https://www.321223.com/cn/our-approach/publications/20230909/?page=4 https://www.321223.com/cn/our-approach/publications/20230909/?page=2 https://www.321223.com/cn/our-approach/publications/20230909/?page=1 https://www.321223.com/cn/our-approach/publications/20230909/ https://www.321223.com/cn/our-approach/publications/20230830/?page=4 https://www.321223.com/cn/our-approach/publications/20230830/?page=2 https://www.321223.com/cn/our-approach/publications/20230830/?page=1 https://www.321223.com/cn/our-approach/publications/20230830/ https://www.321223.com/cn/our-approach/publications/20221215/?page=4 https://www.321223.com/cn/our-approach/publications/20221215/?page=2 https://www.321223.com/cn/our-approach/publications/20221215/?page=1 https://www.321223.com/cn/our-approach/publications/20221215/ https://www.321223.com/cn/our-approach/publications/20220817/?page=4 https://www.321223.com/cn/our-approach/publications/20220817/?page=2 https://www.321223.com/cn/our-approach/publications/20220817/?page=1 https://www.321223.com/cn/our-approach/publications/20220817/ https://www.321223.com/cn/our-approach/publications/20201001/?page=5 https://www.321223.com/cn/our-approach/publications/20201001/?page=4 https://www.321223.com/cn/our-approach/publications/20201001/?page=2 https://www.321223.com/cn/our-approach/publications/20201001/?page=1 https://www.321223.com/cn/our-approach/publications/20201001/ https://www.321223.com/cn/our-approach/publications/20200925/?page=5 https://www.321223.com/cn/our-approach/publications/20200925/?page=4 https://www.321223.com/cn/our-approach/publications/20200925/?page=2 https://www.321223.com/cn/our-approach/publications/20200925/?page=1 https://www.321223.com/cn/our-approach/publications/20200925/ https://www.321223.com/cn/our-approach/publications/20200801/?page=4 https://www.321223.com/cn/our-approach/publications/20200801/?page=2 https://www.321223.com/cn/our-approach/publications/20200801/?page=1 https://www.321223.com/cn/our-approach/publications/20200801/ https://www.321223.com/cn/our-approach/publications/20200121/?page=5 https://www.321223.com/cn/our-approach/publications/20200121/?page=4 https://www.321223.com/cn/our-approach/publications/20200121/?page=2 https://www.321223.com/cn/our-approach/publications/20200121/?page=1 https://www.321223.com/cn/our-approach/publications/20200121/ https://www.321223.com/cn/our-approach/publications/20191219/?page=5 https://www.321223.com/cn/our-approach/publications/20191219/?page=4 https://www.321223.com/cn/our-approach/publications/20191219/?page=2 https://www.321223.com/cn/our-approach/publications/20191219/?page=1 https://www.321223.com/cn/our-approach/publications/20191219/ https://www.321223.com/cn/our-approach/publications/20190920/?page=5 https://www.321223.com/cn/our-approach/publications/20190920/?page=4 https://www.321223.com/cn/our-approach/publications/20190920/?page=2 https://www.321223.com/cn/our-approach/publications/20190920/?page=1 https://www.321223.com/cn/our-approach/publications/20190920/ https://www.321223.com/cn/our-approach/publications/20190701/?page=4 https://www.321223.com/cn/our-approach/publications/20190701/?page=2 https://www.321223.com/cn/our-approach/publications/20190701/?page=1 https://www.321223.com/cn/our-approach/publications/20190701/ https://www.321223.com/cn/our-approach/publications/20190429/?page=5 https://www.321223.com/cn/our-approach/publications/20190429/?page=4 https://www.321223.com/cn/our-approach/publications/20190429/?page=2 https://www.321223.com/cn/our-approach/publications/20190429/?page=1 https://www.321223.com/cn/our-approach/publications/20190429/ https://www.321223.com/cn/our-approach/publications/20190417/?page=4 https://www.321223.com/cn/our-approach/publications/20190417/?page=2 https://www.321223.com/cn/our-approach/publications/20190417/?page=1 https://www.321223.com/cn/our-approach/publications/20190417/ https://www.321223.com/cn/our-approach/publications/20181101/?page=5 https://www.321223.com/cn/our-approach/publications/20181101/?page=4 https://www.321223.com/cn/our-approach/publications/20181101/?page=2 https://www.321223.com/cn/our-approach/publications/20181101/?page=1 https://www.321223.com/cn/our-approach/publications/20181101/ https://www.321223.com/cn/our-approach/publications/20181001/?page=4 https://www.321223.com/cn/our-approach/publications/20181001/?page=2 https://www.321223.com/cn/our-approach/publications/20181001/?page=1 https://www.321223.com/cn/our-approach/publications/20181001/ https://www.321223.com/cn/our-approach/publications/20180906/?page=4 https://www.321223.com/cn/our-approach/publications/20180906/?page=2 https://www.321223.com/cn/our-approach/publications/20180906/?page=1 https://www.321223.com/cn/our-approach/publications/20180906/ https://www.321223.com/cn/our-approach/publications/20180804/?page=4 https://www.321223.com/cn/our-approach/publications/20180804/?page=2 https://www.321223.com/cn/our-approach/publications/20180804/?page=1 https://www.321223.com/cn/our-approach/publications/20180804/ https://www.321223.com/cn/our-approach/publications/20171218/?page=5 https://www.321223.com/cn/our-approach/publications/20171218/?page=4 https://www.321223.com/cn/our-approach/publications/20171218/?page=2 https://www.321223.com/cn/our-approach/publications/20171218/?page=1 https://www.321223.com/cn/our-approach/publications/20171218/ https://www.321223.com/cn/our-approach/publications/20170919/?page=5 https://www.321223.com/cn/our-approach/publications/20170919/?page=4 https://www.321223.com/cn/our-approach/publications/20170919/?page=2 https://www.321223.com/cn/our-approach/publications/20170919/?page=1 https://www.321223.com/cn/our-approach/publications/20170919/ https://www.321223.com/cn/our-approach/publications/20170703/?page=5 https://www.321223.com/cn/our-approach/publications/20170703/?page=4 https://www.321223.com/cn/our-approach/publications/20170703/?page=2 https://www.321223.com/cn/our-approach/publications/20170703/?page=1 https://www.321223.com/cn/our-approach/publications/20170703/ https://www.321223.com/cn/our-approach/publications/20170516/?page=4 https://www.321223.com/cn/our-approach/publications/20170516/?page=2 https://www.321223.com/cn/our-approach/publications/20170516/?page=1 https://www.321223.com/cn/our-approach/publications/20170516/ https://www.321223.com/cn/our-approach/publications/20161229/?page=4 https://www.321223.com/cn/our-approach/publications/20161229/?page=2 https://www.321223.com/cn/our-approach/publications/20161229/?page=1 https://www.321223.com/cn/our-approach/publications/20161229/ https://www.321223.com/cn/our-approach/publications/ https://www.321223.com/cn/our-approach/manufacturing/ https://www.321223.com/cn/our-approach/ https://www.321223.com/cn/news/?page=4 https://www.321223.com/cn/news/?page=3 https://www.321223.com/cn/news/?page=21 https://www.321223.com/cn/news/?page=20 https://www.321223.com/cn/news/?page=2 https://www.321223.com/cn/news/?page=19 https://www.321223.com/cn/news/?page=18 https://www.321223.com/cn/news/?page=1 https://www.321223.com/cn/news/20261009/ https://www.321223.com/cn/news/20260929/ https://www.321223.com/cn/news/20260921/ https://www.321223.com/cn/news/20260914/ https://www.321223.com/cn/news/20260819/ https://www.321223.com/cn/news/20260807/ https://www.321223.com/cn/news/20260804/ https://www.321223.com/cn/news/20260724/ https://www.321223.com/cn/news/20260722/ https://www.321223.com/cn/news/20260716/ https://www.321223.com/cn/news/20260715/ https://www.321223.com/cn/news/20260707/ https://www.321223.com/cn/news/20260622/ https://www.321223.com/cn/news/20260622-1/ https://www.321223.com/cn/news/20260615/ https://www.321223.com/cn/news/20260601/ https://www.321223.com/cn/news/20260521/ https://www.321223.com/cn/news/20260512/ https://www.321223.com/cn/news/20260429/ https://www.321223.com/cn/news/20260428/ https://www.321223.com/cn/news/20260309/ https://www.321223.com/cn/news/20260306/ https://www.321223.com/cn/news/20260213/ https://www.321223.com/cn/news/20260112/ https://www.321223.com/cn/news/20251230/ https://www.321223.com/cn/news/20251229/ https://www.321223.com/cn/news/20251208/ https://www.321223.com/cn/news/20190129/ https://www.321223.com/cn/news/ https://www.321223.com/cn/investors/listing-documents/ https://www.321223.com/cn/investors/ir-contact/ https://www.321223.com/cn/investors/financial-reports/ https://www.321223.com/cn/investors/corporate-governance/ https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/webcasts/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/通用型car-t产品ct0596及ct1190b的积极临床数据/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/ͨ����car-t��Ʒct0596��ct1190b�Ļ����ٴ�����/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20261026/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20260601/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct1190b/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2026-eha-first-in-human-study-of-ct0596/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251207/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20251119/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-ims-long-term-follow-up-of-zevor-cel-in-patients-with-relapsed-refractory-multiple-myeloma/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-esmo-adjuvant-therapy-with-claudin18-2-specific-car-t-cells-satri-cel-in-high-risk-pancreatic-cancer-ct041-st-05/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-eha-a-phase-i-study-of-gprc5d-targeting-car-t-cell-therapy-ct071-for-high-risk-newly-diagnosed-multiple-myeloma/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2025-asco-claudin18-2-specific-car-t-cells-satri-cel-versus-treatment-of-physician-s-choice-tpc-for-previously-treated-advanced-gastric-or-gastroesophageal-junction-cancer-g-gejc-primary-results-from-a-randomized-open-label-phase-ii-trial-c/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20240119/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-phase-2-study-of-fully-human-bcma-targeting-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-eha-first-in-human/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-subgroup-analyses-of-phase-2-study/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-gprc5d-targeted-car-t-cell-therapy-ct071-for-the-treatment-of-refractory-relapsed-multiple-myeloma/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-ash-a-first-in-human-stud/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2024-asco-claudin18-2-targeted-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-gastrointestinal-cancers-final-results-of-ct041-cg4006-phase-1-trial/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/20231212/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-sitc-case-report-metastatic/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-gi-a-multicenter-phase-1-study-of-ab011-a-recombinant-humanized-anti-cldn18-2-monoclonal-antibody-ab011-as-monotherapy-and-combined-with-capecitabine-and-oxaliplatin-capox-in-patients-with-advanced-solid-tumors/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-2/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-asco-1/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2023-aacr/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-car-tcr-summit/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-ash-phase-study-of-fully-human-bcma-targeted-car-t-cells-zevorcabtagene-autoleucel-in-patients-with-relapsed-refractory-multiple-myeloma/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-safety-tolerability-and-preliminary-efficacy-results-in-patients-with-advanced-gastric-gastroesophageal-junction-adenocarcinoma-from-a-phase-ib-ii-study-of-cldn18-2-car-t-cell-therapy-ct041/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2022-asco-multicenter-phase-1b-trial-of-salvage-ct041-cldn18-2-specific-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-advanced-gastric-and-pancreatic-adenocarcinoma/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=6 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-esmo-ct041-oral-presentation/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-2821/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/2021-ash-ct053-poster-1751/ https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/%E9%80%9A%E7%94%A8%E5%9E%8Bcar-t%E4%BA%A7%E5%93%81ct0596%E5%8F%8Act1190b%E7%9A%84%E7%A7%AF%E6%9E%81%E4%B8%B4%E5%BA%8A%E6%95%B0%E6%8D%AE/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/presentations/ https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/carsgen-therapeutics-corporate-deck/ https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/corporate-deck/ https://www.321223.com/cn/investors/corporate-deck-presentations/?page=5 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=4 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=3 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=2 https://www.321223.com/cn/investors/corporate-deck-presentations/?page=1 https://www.321223.com/cn/investors/corporate-deck-presentations/ https://www.321223.com/cn/investors/announcements-circulars/ https://www.321223.com/cn/investors/ https://www.321223.com/cn/disclaimer/ https://www.321223.com/cn/contact-us/ https://www.321223.com/cn/careers/join-us/ https://www.321223.com/cn/careers/ https://www.321223.com/cn/about-us/vision-mission-values/ https://www.321223.com/cn/about-us/partnering/ https://www.321223.com/cn/about-us/leadership/ https://www.321223.com/cn/about-us/company-overview/ https://www.321223.com/cn/about-us/ https://www.321223.com/cn/" https://www.321223.com/cn/ https://www.321223.com/ https://www.321223.com" https://www.321223.com http://www.321223.com<#if http://www.321223.com/html/web/xinwenzhongxin/shipinzhuanqu/index.html http://www.321223.com/html/web/xinwenzhongxin/fangdaxinwen/index.html http://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/index.html http://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2103055327044489218.html http://www.321223.com/html/web/touziyuhezuo/zhaobiaogonggao/2102682494330130434.html http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/zhongxingshangye/index.html http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/yihangkeji/index.html http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/xinshengfeixiang/index.html http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/shouhangzhishengji/index.html http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/index.html http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/haihangkonggu/index.html http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/fangdategang/index.html http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/fangdatansu/index.html http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/dongbeizhiyao/index.html http://www.321223.com/html/web/touziyuhezuo/shangshigongsi/chengdutancai/index.html http://www.321223.com/html/web/shehuizeren/zhichiguofang/index.html http://www.321223.com/html/web/shehuizeren/yifanashui/index.html http://www.321223.com/html/web/shehuizeren/shehuigongyi/index.html http://www.321223.com/html/web/shehuizeren/jienenghuanbao/index.html http://www.321223.com/html/web/shehuizeren/baozhangjiuye/index.html http://www.321223.com/html/web/rencaifazhan/zhaopingonggao/index.html http://www.321223.com/html/web/guanyuwomen/zuzhijiagou/index.html http://www.321223.com/html/web/guanyuwomen/fazhanlicheng/index.html http://www.321223.com/html/web/guanyuwomen/fangdarongyu/index.html http://www.321223.com/html/web/guanyuwomen/fangdajianjie/index.html http://www.321223.com/html/web/dangjianwenhua/xingfufangda/index.html http://www.321223.com/html/web/dangjianwenhua/qiyelinian/index.html http://www.321223.com/html/web/dangjianwenhua/dangqunhuodong/index.html http://www.321223.com/html/web/chengyuandanwei/yiyao/index.html http://www.321223.com/html/web/chengyuandanwei/tansu/index.html http://www.321223.com/html/web/chengyuandanwei/tansu/ https:/www.cdcarbon.cn/intro/3.html http://www.321223.com/html/web/chengyuandanwei/tansu/ https:/www.cd-ts.cn/about/7.html http://www.321223.com/html/web/chengyuandanwei/tansu/ https:/fushuncarbon.com http://www.321223.com/html/web/chengyuandanwei/tansu/ http:/fdtsgs.com http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952972548200914946.html http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952971930770006018.html http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952969997875339266.html http://www.321223.com/html/web/chengyuandanwei/tansu/ /html/web/chengyuandanwei/tansu/1952966690133958658.html http://www.321223.com/html/web/chengyuandanwei/shangye/index.html http://www.321223.com/html/web/chengyuandanwei/hangkong/index.html http://www.321223.com/html/web/chengyuandanwei/gangtie/index.html http://www.321223.com/html/web/chengyuandanwei/gangtie/ https:/www.jxfangda-steels.com/index/about/id/1.html http://www.321223.com/html/web/chengyuandanwei/gangtie/ https:/www.fddzsteel.com/dg_gywm/dg_qyjj/cindex1.html http://www.321223.com/html/web/chengyuandanwei/gangtie/ http:/www.scdesheng.com/ http://www.321223.com/html/web/chengyuandanwei/gangtie/ http:/www.nhi.com.cn/html/web/guanyuwomen/gongsijianjie/index.html http://www.321223.com/html/web/chengyuandanwei/gangtie/ http:/www.fangda-specialsteels.com/web/index.aspx http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/2062069973823197186.html http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952982209025204225.html http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952981773291544577.html http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952981140610146305.html http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952980763097620482.html http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952980411455561730.html http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952980023696351234.html http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952978003895705602.html http://www.321223.com/html/web/chengyuandanwei/gangtie/ /html/web/chengyuandanwei/gangtie/1952977484364046338.html http://www.321223.com/column/95/ http://www.321223.com/column/94/ http://www.321223.com/column/92/ http://www.321223.com/column/138/ http://www.321223.com/ http://www.321223.com https://www.yzr.com.cn/micro/main/aboutus/63ca0a89b5240a7602621d60 http://www.321223.com https://www.ykfdyy.com/ http://www.321223.com https://www.westair.cn/stcontent/menupage/f9515923-5f75-4801-a3f3-daf09cdbb133/fd170793-0f42-499e-b03a-bc0632fe0cc5/9f991f7f-89e1-4c22-b1c7-411156b46ef0 http://www.321223.com https://www.urumqi-air.com/micro/main/aboutus/641159f50c682c7801e5a149 http://www.321223.com https://www.tjys.com.cn/html/web/guanyuyihang/gongsijianjie/index.html http://www.321223.com https://www.tianjin-air.com/stcontent/menupage/0bbd75f1-bc38-41c6-95f4-4e3644aa70b8/7c0ff667-57c6-4de5-8e7f-e9fa5b0d4ccb/766eab66-6b64-48f7-b6de-b2ab8c2e8742 http://www.321223.com https://www.nepharm.com.cn/html/web/liaojiewomen/gongsijianjie/index.html http://www.321223.com https://www.luckyair.net/micro/main/aboutus/641d4bbf230c607e69a9a99f http://www.321223.com https://www.jdair.net/micro/main/article/64599c7160a9be4d4434c960 http://www.321223.com https://www.hnasatc.edu.cn/xxgk/xxjj.htm http://www.321223.com https://www.hnair.com/guanyuhaihang/hhgs/gsjj/ http://www.321223.com https://www.hnacargo.com/Portal2/AboutUs.aspx http://www.321223.com https://www.gxairlines.com/stdair/tcms?directoryName=foot&fileName=CompanyAndOverview http://www.321223.com https://www.fuzhou-air.cn/micro/main/aboutus/63db6994257effa4641ba390 http://www.321223.com https://www.fd-yy.com/html/web/guanyuwomen/yiyuanjianjie/index.html http://www.321223.com https://www.deerjet.com/about/advantage.html http://www.321223.com https://www.airchangan.com/content/c2aafb9c-c9a1-414e-8182-000a082ff315 http://www.321223.com http://www.zxbusiness.com/web/gyzx?nid=1 http://www.321223.com http://www.hnatechnic.com/html/web/aboutus/gongsijianjie/index.html http://www.321223.com http://www.3-hospital-cqmu.com http://www.321223.com /html/web/chengyuandanwei/hangkong/1953010391426195457.html http://www.321223.com /html/web/chengyuandanwei/hangkong/1953007446785712129.html http://www.321223.com